Telomir Pharmaceuticals (TELO) Short-Term Debt issuances (2023 - 2024)

Telomir Pharmaceuticals (TELO) posted Short-Term Debt issuances of $101000.0 for Q1 2024, down 11.79% sequentially from $114500.0 in Q4 2023.

Telomir Pharmaceuticals (TELO) Short-Term Debt issuances (2023 - 2024) Analysis & Trends

Telomir Pharmaceuticals has reported Short-Term Debt issuances for 2 years, with the latest figure at $101000.0 in Q1 2024.

Quarterly Short-Term Debt issuances changed N/A year-over-year to $101000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $101000.0 (changed N/A YoY) and the FY2024 annual result came in at $101000.0, down 93.05% from the prior year.
Short-Term Debt issuances slipped to $101000.0 in Q1 2024 per TELO's latest filing, from $114500.0 in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $850000.0 in Q3 2023 and troughed at $101000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Telomir Pharmaceuticals	69.05 Mn	69.05 Mn	-	-

Download Data